The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: A pilot study

European Radiology

Volumn 21, Issue 2, 2011, Pages 281-290

  Lewin, Maïté ^a,b   Fartoux, Laetitia ^a   Vignaud, Alexandre ^c   Arrivé, Lionel ^a,b   Menu, Yves ^a,b   Rosmorduc, Olivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c France and Siemens Medical Department   (France)

Author keywords

Anti angiogenics; Diffusion coefficient; Hepatocellular carcinoma; Perfusion fraction; Response assessment; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FEMALE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER PERFUSION; MALE; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PYRIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 79951950818     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1914-4     Document Type: Article

References (31)

1. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
2. AR Padhani G Liu DM Koh, et al. 2009 Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 102 125 1:CAS:528:DC%2BD1MXhvVOls70%3D 19186405
3. DM Koh DJ Collins 2007 Diffusion-weighted MRI in the body: applications and challenges in oncology AJR Am J Roentgenol 188 1622 1635 10.2214/AJR.06.1403 17515386 (Pubitemid 46866868)
4. D Le Bihan E Breton D Lallemand, et al. 1988 Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging Radiology 168 497 505 3393671
5. I Yamada W Aung Y Himeno, et al. 1999 Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging Radiology 210 617 623 1:STN:280:DyaK1M3itlyltw%3D%3D 10207458 (Pubitemid 29124018)
6. M Lewin A Poujol-Robert PY Boëlle, et al. 2007 Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C Hepatology 46 658 665 1:CAS:528:DC%2BD2sXhtFWhsrzP 10.1002/hep.21747 17663420 (Pubitemid 47436110)
7. A Luciani A Vignaud M Cavet, et al. 2008 Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study Radiology 249 891 899 10.1148/radiol.2493080080 19011186
8. B Taouli DM Koh 2010 Diffusion-weighted MR imaging of the liver Radiology 254 47 66 10.1148/radiol.09090021 20032142
9. IR Kamel E Liapi DK Reyes, et al. 2009 Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemobolization as detected with MR imaging Radiology 250 466 473 10.1148/radiol.2502072222 19188315
10. CY Chen CW Li YT Kuo, et al. 2006 Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience Radiology 239 448 456 10.1148/radiol.2392042202 16569781
11. C Schraml NF Schwenzer P Martirosian, et al. 2009 Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results AJR Am J Roentgenol 193 W301 W307 10.2214/AJR.08.2289 19770299
12. RK Jain DG Duda CG Willett, et al. 2009 Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 327 338 1:CAS:528:DC%2BD1MXms12gtb4%3D 10.1038/nrclinonc.2009.63 19483739
13. D Semela JF Dufour 2004 Angiogenesis and hepatocellular carcinoma J Hepatol 41 864 880 10.1016/j.jhep.2004.09.006 15519663 (Pubitemid 39434320)
14. J Bruix M Sherman Practice Guidelines Committee, American Association for the Study of Liver Diseases 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 10.1002/hep.20933 16250051 (Pubitemid 43112690)
15. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 10.1016/j.ejca.2008.10.026 19097774
16. JM Llovet AM Di Bisceglie J Bruix, et al. 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 698 711 10.1093/jnci/djn134 18477802
17. A Forner C Ayuso M Varela, et al. 2009 Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 616 623 10.1002/cncr.24050 19117042
18. DM Koh M Blackledge DJ Collins, et al. 2009 Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial Eur Radiol 19 2728 2738 10.1007/s00330-009-1469-4 19547986
19. M Lewin L Arrivé C Lacombe, et al. 2010 Diffusion-weighted MR imaging of liver pathology: principles and clinical applications J Radiol 91 11 26 1:STN:280:DC%2BC3c7ms12isQ%3D%3D 10.1016/S0221-0363(10)70002-0 20212373
20. B Taouli V Vilgrain E Dumont, et al. 2003 Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients Radiology 226 71 78 10.1148/radiol.2261011904 12511671 (Pubitemid 36163910)
21. T Parikh SJ Drew VS Lee, et al. 2008 Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging Radiology 246 812 822 10.1148/radiol.2463070432 18223123
22. S Gourtsoyianni N Papanikolaou S Yarmenitis, et al. 2008 Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions Eur Radiol 18 486 492 10.1007/s00330-007-0798-4 17994317
23. T Namimoto Y Yamashita S Sumi, et al. 1997 Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging Radiology 204 739 744 1:STN:280:DyaK2svisVegsg%3D%3D 9280252 (Pubitemid 27369034)
24. T Kim T Murakami S Takahashi, et al. 1999 Diffusion-weighted single-shot echoplanar MR imaging for liver disease AJR Am J Roentgenol 173 393 398 1:STN:280:DyaK1MzlslaisA%3D%3D 10430143 (Pubitemid 29347365)
25. M Bruegel K Holzapfel J Gaa, et al. 2008 Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique Eur Radiol 18 477 485 10.1007/s00330-007-0785-9 17960390 (Pubitemid 351248179)
26. IR Kamel DA Bluemke D Ramsey, et al. 2003 Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma AJR Am J Roentgenol 181 708 710 12933464 (Pubitemid 37021839)
27. L Mannelli S Kim CH Hajdu, et al. 2009 Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver AJR Am J Roentgenol 193 1044 1052 10.2214/AJR.08.1461 19770328
28. M Horger UM Lauer C Schraml, et al. 2009 Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib BMC Cancer 9 208 10.1186/1471-2407-9-208 19558720
29. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 1:CAS:528:DC%2BD2MXnvFar 10.1126/science.1104819 15637262 (Pubitemid 40093472)
30. N Mitsuhashi S Kobayashi T Doki, et al. 2008 Clinical significance of a-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma J Gastroenterol Hepatol 23 e189 e197 1:CAS:528:DC%2BD1cXhsVaitr%2FM 10.1111/j.1440-1746.2008.05340.x 18466288 (Pubitemid 352019435)
31. R Lencioni JM Llovet 2010 Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 52 60 1:CAS:528:DC%2BC3cXjvFCqtbk%3D 10.1055/s-0030-1247132 20175033